By designating just one reference listed drug given that the common to which all generic versions needs to be demonstrated to become bioequivalent, FDA hopes to avoid doable considerable variations between generic drugs and their manufacturer name counterpart. -The situations of administration needs to be dispersed as evenly as feasible througho